Literature DB >> 10230352

Galectin fingerprinting in tumor diagnosis. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign vs malignant uterine smooth muscle tumors.

G Schwarz1, M Remmelink, C Decaestecker, I Gielen, V Budel, M Burchert, F Darro, A Danguy, H J Gabius, I Salmon, R Kiss.   

Abstract

Cell-matrix interactions are governed by a distinct set of proteins, with 2 nonintegrin laminin-binding proteins, galectin-1 and galectin-3, providing 1 aspect. The expression patterns of laminin and the 2 galectins and galectin binding sites were quantitatively determined by means of computer-assisted microscopy with the aim of differentiating between 16 leiomyomas and 10 leiomyosarcomas of the uterus. Three quantitative variables were computed for each of the 5 histochemical markers: labeling index, which describes the percentage of tissue area specifically stained by a given marker; mean optical density which reflects the concentration of the marker; and concentrational heterogeneity, which characterizes the degree of heterogeneity of the marker distribution in the tumor tissue areas. The results reveal evident differences in the galectin-3-related parameters in the 2 tumors groups. Whereas the concentration of galectin-3 binding sites was significantly (P = .01) weaker in the leiomyosarcomas than in the leiomyomas, the percentages of tumor tissue expressing galectin-3 (P = .02) and its binding sites (P = .002) were significantly higher in the leiomyosarcomas than in the leiomyomas. Although significantly (P = .02) higher, the concentration of laminin was more heterogeneously distributed (P = .01) in the leiomyosarcomas than in the leiomyomas. In contrast, the levels of expression of galectin-1 and its accessible binding sites remained similar for both the leiomyomas and the leiomyosarcomas. Finally we document how the levels of expression of galectin-3 and its binding sites can be of assistance in reliably differentiating leiomyomas from leiomyosarcomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10230352     DOI: 10.1093/ajcp/111.5.623

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Galectin-3 expression is associated with bladder cancer progression and clinical outcome.

Authors:  Giacomo Canesin; Pilar Gonzalez-Peramato; Joan Palou; Manuel Urrutia; Carlos Cordón-Cardo; Marta Sánchez-Carbayo
Journal:  Tumour Biol       Date:  2010-04-17

2.  Detection of galectin-3 in tear fluid at disease states and immunohistochemical and lectin histochemical analysis in human corneal and conjunctival epithelium.

Authors:  E Hrdlicková-Cela; J Plzák; K Smetana; Z Mĕlková; H Kaltner; M Filipec; F T Liu; H J Gabius
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

3.  Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor.

Authors:  N Nagy; Y Bronckart; I Camby; H Legendre; H Lahm; H Kaltner; Y Hadari; P Van Ham; P Yeaton; J-C Pector; Y Zick; I Salmon; A Danguy; R Kiss; H-J Gabius
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

4.  Immunoexpression of galectin-3 in colorectal cancer and its relationship with survival.

Authors:  Luciana Zaia Povegliano; Celina Tizuko Fujiyama Oshima; Flávio de Oliveira Lima; Pedro Luiz Andrade Scherholz; Nora Manoukian Forones
Journal:  J Gastrointest Cancer       Date:  2011-12

5.  Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer.

Authors:  Hafiz Ahmed; Francesco Cappello; Vito Rodolico; Gerardo R Vasta
Journal:  Transl Oncol       Date:  2009-08-18       Impact factor: 4.243

6.  Serum Galectin-3: diagnostic value for papillary thyroid carcinoma.

Authors:  Erdem Yılmaz; Tamer Karşıdağ; Cihad Tatar; Sefa Tüzün
Journal:  Ulus Cerrahi Derg       Date:  2015-04-09

7.  Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.

Authors:  Anke Vanderstraeten; Catherine Luyten; Godelieve Verbist; Sandra Tuyaerts; Frederic Amant
Journal:  Cancer Immunol Immunother       Date:  2014-06       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.